Efpeglenatide is being subcutaneously administered once per week as a long-acting GLP-1 receptor agonist. Frias JP and colleagues conducted a study under the title...
With the increasing prevalence of diabetes, new treatment approaches are in need of time. Rosenstock J and colleagues conducted research under the title “Efficacy...
Once-weekly (OW) subcutaneous semaglutide is a GLP-1RA supported for the treatment of type 2 diabetes (T2D) at dosages of 0.5 mg and 1.0 mg....
Weight loss proves to be beneficial for patients with diabetes. A combination of lifestyle intervention, behavioral modifications and pharmacotherapy helps improve various cardio-metabolic risk...
Type 2 Diabetes patients have multiple associated co-morbidities such as overweight or obesity and Diabetes medications often result in weight gain which puts additional...
Obesity is a chronic condition that impacts several aspects of life. Long-term weight maintenance is a challenging task. Short-term treatment with anti-obesity medications fail...
